Chemoprevention of prostate cancer: What can be recommended to patients?

Janet L. Colli, Christopher Amling

Research output: Contribution to journalArticle

Abstract

Prostate cancer is third to lung and colon cancer as the cause of cancer-related deaths in American men. It is estimated that there will have been more than 28,000 deaths and 186,000 new cases in 2008 that will impose a significant burden on national health care costs. Chemoprevention aims to reduce both incidence and mortality through the use of agents to prevent, reverse, or delay the carcinogenic process. This study provides clinicians with information on some chemoprevention agents that have been considered to reduce prostate cancer risks, including 5-α-reductase inhibitors; statins (a class of compounds used to reduce cholesterol); NSAIDs; selenium; vitamins E and D; lycopene; allium vegetables (garlic, scallions, onions, chives, and leeks); soy/isoflavones; and green tea polyphenols. The evidence to support prostate cancer risk reduction benefits for each chemoprevention agent based on a review of the literature is provided.

Original languageEnglish (US)
Pages (from-to)47-53
Number of pages7
JournalCurrent Prostate Reports
Volume7
Issue number2
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Chemoprevention
Prostatic Neoplasms
Onions
Chive
Allium
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Garlic
Isoflavones
Polyphenols
Non-Steroidal Anti-Inflammatory Agents
Tea
Risk Reduction Behavior
Selenium
Vitamin E
Vitamin D
Vegetables
Health Care Costs
Colonic Neoplasms
Lung Neoplasms
Oxidoreductases

ASJC Scopus subject areas

  • Urology

Cite this

Chemoprevention of prostate cancer : What can be recommended to patients? / Colli, Janet L.; Amling, Christopher.

In: Current Prostate Reports, Vol. 7, No. 2, 07.2009, p. 47-53.

Research output: Contribution to journalArticle

@article{412a7cfb47b34f49b0c1fa85e35d3f7a,
title = "Chemoprevention of prostate cancer: What can be recommended to patients?",
abstract = "Prostate cancer is third to lung and colon cancer as the cause of cancer-related deaths in American men. It is estimated that there will have been more than 28,000 deaths and 186,000 new cases in 2008 that will impose a significant burden on national health care costs. Chemoprevention aims to reduce both incidence and mortality through the use of agents to prevent, reverse, or delay the carcinogenic process. This study provides clinicians with information on some chemoprevention agents that have been considered to reduce prostate cancer risks, including 5-α-reductase inhibitors; statins (a class of compounds used to reduce cholesterol); NSAIDs; selenium; vitamins E and D; lycopene; allium vegetables (garlic, scallions, onions, chives, and leeks); soy/isoflavones; and green tea polyphenols. The evidence to support prostate cancer risk reduction benefits for each chemoprevention agent based on a review of the literature is provided.",
author = "Colli, {Janet L.} and Christopher Amling",
year = "2009",
month = "7",
doi = "10.1007/s11918-009-0008-8",
language = "English (US)",
volume = "7",
pages = "47--53",
journal = "Current Prostate Reports",
issn = "1544-1865",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - Chemoprevention of prostate cancer

T2 - What can be recommended to patients?

AU - Colli, Janet L.

AU - Amling, Christopher

PY - 2009/7

Y1 - 2009/7

N2 - Prostate cancer is third to lung and colon cancer as the cause of cancer-related deaths in American men. It is estimated that there will have been more than 28,000 deaths and 186,000 new cases in 2008 that will impose a significant burden on national health care costs. Chemoprevention aims to reduce both incidence and mortality through the use of agents to prevent, reverse, or delay the carcinogenic process. This study provides clinicians with information on some chemoprevention agents that have been considered to reduce prostate cancer risks, including 5-α-reductase inhibitors; statins (a class of compounds used to reduce cholesterol); NSAIDs; selenium; vitamins E and D; lycopene; allium vegetables (garlic, scallions, onions, chives, and leeks); soy/isoflavones; and green tea polyphenols. The evidence to support prostate cancer risk reduction benefits for each chemoprevention agent based on a review of the literature is provided.

AB - Prostate cancer is third to lung and colon cancer as the cause of cancer-related deaths in American men. It is estimated that there will have been more than 28,000 deaths and 186,000 new cases in 2008 that will impose a significant burden on national health care costs. Chemoprevention aims to reduce both incidence and mortality through the use of agents to prevent, reverse, or delay the carcinogenic process. This study provides clinicians with information on some chemoprevention agents that have been considered to reduce prostate cancer risks, including 5-α-reductase inhibitors; statins (a class of compounds used to reduce cholesterol); NSAIDs; selenium; vitamins E and D; lycopene; allium vegetables (garlic, scallions, onions, chives, and leeks); soy/isoflavones; and green tea polyphenols. The evidence to support prostate cancer risk reduction benefits for each chemoprevention agent based on a review of the literature is provided.

UR - http://www.scopus.com/inward/record.url?scp=68349101197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349101197&partnerID=8YFLogxK

U2 - 10.1007/s11918-009-0008-8

DO - 10.1007/s11918-009-0008-8

M3 - Article

AN - SCOPUS:68349101197

VL - 7

SP - 47

EP - 53

JO - Current Prostate Reports

JF - Current Prostate Reports

SN - 1544-1865

IS - 2

ER -